ZYMEWORKS INC. Accumulated Other Comprehensive Income
ZYMEWORKS INC. (ZYME) had Accumulated Other Comprehensive Income of -$6.69 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.69M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.57M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.08M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.05M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$6.69M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$6.57M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$6.08M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$6.05M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$6.34M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$6.41M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$6.95M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$6.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | -$7.90M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$7.72M 10-Q · filed 2024-05-02 |
| 2023-12-31 | -$6.60M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$8.30M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$7.81M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$5.94M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$6.66M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$6.66M 10-Q · filed 2022-11-08 |
| 2021-12-31 | -$6.66M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |